Intensity Therapeutics Q1 2025 Earnings Report
Key Takeaways
Intensity Therapeutics reported a lower net loss in Q1 2025 compared to the same period last year, primarily due to reduced research and development and general and administrative expenses. The company paused new site activations and patient enrollments for the INVINCIBLE-3 study due to funding constraints, prioritizing funding for the INVINCIBLE-4 study.
Net loss for Q1 2025 was $3.3 million, an improvement from the $4.6 million loss in Q1 2024.
Research and development expenses decreased to $2.2 million in Q1 2025 from $2.8 million in Q1 2024.
General and administrative expenses decreased to $1.2 million in Q1 2025 from $1.9 million in Q1 2024.
The company paused new site activations and patient enrollments for the INVINCIBLE-3 study due to funding constraints.
Intensity Therapeutics
Intensity Therapeutics
Forward Guidance
The company is continuing to treat patients already enrolled in the INVINCIBLE-3 study and is working with partners in Switzerland and France to find patients for the INVINCIBLE-4 study. Additional funding is needed to resume the INVINCIBLE-3 study enrollment and site activation.
Positive Outlook
- Continued progress in important programs despite market volatility and funding constraints.
- Several patients in the sarcoma study (INVINCIBLE-3) showed high levels of necrosis in injected tumors.
- INVINCIBLE-4 study is actively seeking patients in Switzerland and France.
- Raised $2.35 million in a public offering in April 2025.
- Belief in the potential of their drug to positively impact patients.
Challenges Ahead
- Paused new site activations and patient enrollments for the INVINCIBLE-3 study.
- Funding constraints are impacting the ability to advance the INVINCIBLE-3 study.
- Need additional funding to resume the INVINCIBLE-3 study enrollment and site activation.
- High volatility in the markets impacting funding.
- No specific timelines provided for resuming full INVINCIBLE-3 activities.